Anti-myeloma activity of endogenous and adoptively transferred activated natural killer cells in experimental multiple myeloma model

Experimental Hematology

Volumn 35, Issue 12, 2007, Pages 1839-1846

  Alici, Evren ^a,b   Konstantinidis, Kyriakos V ^a,b   Sutlu, Tolga ^a   Aints, Alar ^a   Gahrton, Gösta ^a   Ljunggren, Hans Gustaf ^b   Dilber, M Sirac ^a  

^a KAROLINSKA UNIVERSITY HOSPITAL   (Sweden)

^b KAROLINSKA INSTITUTE   (Sweden)

Author keywords

[No Author keywords available]

Indexed keywords

CD8 ANTIGEN; MONOCLONAL ANTIBODY; MONOCLONAL ANTIBODY NK1.1; RECOMBINANT INTERLEUKIN 2; UNCLASSIFIED DRUG;

ADOPTIVE IMMUNOTHERAPY; ADOPTIVE TRANSFER; ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL MODEL; ANTINEOPLASTIC ACTIVITY; ARTICLE; CANCER IMMUNOTHERAPY; CANCER MODEL; CANCER RESISTANCE; CANCER SURVIVAL; CELL MIGRATION; CELL THERAPY; CONTROLLED STUDY; FEMALE; HOST RESISTANCE; MALE; MOUSE; MULTIPLE MYELOMA; NATURAL KILLER CELL; NONHUMAN; PRIORITY JOURNAL; SPLEEN CELL; SURVIVAL TIME;

ADOPTIVE TRANSFER; ANIMALS; FLOW CYTOMETRY; INTERLEUKIN-2; KILLER CELLS, NATURAL; LYMPHOCYTE ACTIVATION; MICE; MULTIPLE MYELOMA;

MUS;

EID: 36148984928     PISSN: 0301472X     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.exphem.2007.08.006     Document Type: Article

References (32)

1. Kuehl W.M., and Bergsagel P.L. Multiple myeloma: evolving genetic events and host interactions. Nat Rev 2 (2002) 175-187
2. Lokhorst H.M., Schattenberg A., Cornelissen J.J., et al. Donor lymphocyte infusions for relapsed multiple myeloma after allogeneic stem-cell transplantation: predictive factors for response and long-term outcome. J Clin Oncol 18 (2000) 3031-3037
3. Gahrton G., Tura S., Ljungman P., et al. Allogeneic bone marrow transplantation in multiple myeloma. European Group for Bone Marrow Transplantation. N Engl J Med 325 (1991) 1267-1273
4. Gahrton G. Progress in hematopoietic stem cell transplantation in multiple myeloma. Curr Opin Hematol 12 (2005) 463-470
5. Crawley C., Lalancette M., Szydlo R., et al. Outcomes for reduced-intensity allogeneic transplantation for multiple myeloma: an analysis of prognostic factors from the Chronic Leukaemia Working Party of the EBMT. Blood 105 (2005) 4532-4539
6. Davies F.E., Raje N., Hideshima T., et al. Thalidomide and immunomodulatory derivatives augment natural killer cell cytotoxicity in multiple myeloma. Blood 98 (2001) 210-216
7. Attal M., Harousseau J.L., Stoppa A.M., et al. A prospective, randomized trial of autologous bone marrow transplantation and chemotherapy in multiple myeloma. Intergroupe Francais du Myelome. [see comments]. N Engl J Med 335 (1996) 91-97
8. Child J.A., Morgan G.J., Davies F.E., et al. High-dose chemotherapy with hematopoietic stem-cell rescue for multiple myeloma. N Engl J Med 348 (2003) 1875-1883
9. Smith A., Wisloff F., and Samson D. Guidelines on the diagnosis and management of multiple myeloma 2005. Br J Haematol 132 (2006) 410-451
10. Li Y., Bendandi M., Deng Y., et al. Tumor-specific recognition of human myeloma cells by idiotype-induced CD8(+) T cells. Blood 96 (2000) 2828-2833
11. Reichardt V.L., Okada C.Y., Liso A., et al. Idiotype vaccination using dendritic cells after autologous peripheral blood stem cell transplantation for multiple myeloma-a feasibility study. Blood 93 (1999) 2411-2419
12. Pellat-Deceunynck C. Tumour-associated antigens in multiple myeloma. Br J Haematol 120 (2003) 3-9
13. Turtle C.J., Brown R.D., Joshua D.E., and Hart D.N. DC in multiple myeloma immunotherapy. Cytotherapy 6 (2004) 128-137
14. Reichardt V.L., and Brossart P. Dendritic cells in clinical trials for multiple myeloma. Methods Mol Med 109 (2005) 127-136
15. Trinchieri G. Biology of natural killer cells. Adv Immunol 47 (1989) 187-376
16. Kiessling R., Klein E., Pross H., and Wigzell H. "Natural" killer cells in the mouse. II. Cytotoxic cells with specificity for mouse Moloney leukemia cells. Characteristics of the killer cell. Eur J Immunol 5 (1975) 117-121
17. Kiessling R., Klein E., and Wigzell H. "Natural" killer cells in the mouse. I. Cytotoxic cells with specificity for mouse Moloney leukemia cells. Specificity and distribution according to genotype. Eur J Immunol 5 (1975) 112-117
18. Kim S., Prentice H.G., Mehta A.B., and Yokoyama W.M. In vivo natural killer cell activities revealed by natural killer cell-deficient mice. Br J Haematol 75 (1990) 2731-2736
19. Radl J., De Glopper E.D., Schuit H.R., and Zurcher C. Idiopathic paraproteinemia. II. Transplantation of the paraprotein-producing clone from old to young C57BL/KaLwRij mice. J Immunol 122 (1979) 609-613
20. Radl J., Croese J.W., Zurcher C., Van den Enden-Vieveen M.H., and de Leeuw A.M. Animal model of human disease. Multiple myeloma. Am J Pathol 132 (1988) 593-597
21. Radl J. Age-related monoclonal gammapathies: clinical lessons from the aging C57BL mouse. Immunol Today 11 (1990) 234-236
22. Manning L.S., Berger J.D., O'Donoghue H.L., Sheridan G.N., Claringbold P.G., and Turner J.H. A model of multiple myeloma: culture of 5T33 murine myeloma cells and evaluation of tumorigenicity in the C57BL/KaLwRij mouse. Br J Cancer 66 (1992) 1088-1093
23. Radl J. Multiple myeloma and related disorders. Lessons from an animal model. Pathol Biol (Paris) 47 (1999) 109-114
24. Alici E., Konstantinidis K.V., Aints A., Dilber M.S., and Abedi-Valugerdi M. Visualization of 5T33 myeloma cells in the C57BL/KaLwRij mouse: establishment of a new syngeneic murine model of multiple myeloma. Exp Hematol 32 (2004) 1064-1072
25. Arase H., Saito T., Phillips J.H., and Lanier L.L. Cutting edge: the mouse NK cell-associated antigen recognized by DX5 monoclonal antibody is CD49b ({alpha}2 integrin, very late antigen-2). J Immunol 167 (2001) 1141-1144
26. Manning L.S., Chamberlain N.L., Leahy M.F., and Cordingley F.T. Assessment of the therapeutic potential of cytokines, cytotoxic drugs and effector cell populations for the treatment of multiple myeloma using the 5T33 murine myeloma model. Immunol Cell Biol 73 (1995) 326-332
27. Grimm E.A., Mazumder A., Zhang H.Z., and Rosenberg S.A. Lymphokine-activated killer cell phenomenon. Lysis of natural killer-resistant fresh solid tumor cells by interleukin 2-activated autologous human peripheral blood lymphocytes. J Exp Med 155 (1982) 1823-1841
28. Wen Y.J., Min R., Tricot G., Barlogie B., and Yi Q. Tumor lysate-specific cytotoxic T lymphocytes in multiple myeloma: promising effector cells for immunotherapy. Blood 99 (2002) 3280-3285
29. Asea, and Stein S. Signalling through NK1.1 triggers NK cells to die but induces NK T cells to produce interleukin-4. Immunology 93 (1998) 296-305
30. Wang M., Ellison C.A., Gartner J.G., and HayGlass K.T. Natural killer cell depletion fails to influence initial CD4 T cell commitment in vivo in exogenous antigen-stimulated cytokine and antibody responses. J Immunol 160 (1998) 1098-1105
31. Malek T.R., and Bayer A.L. Tolerance, not immunity, crucially depends on IL-2. Nat Rev Immunol 4 (2004) 665-674
32. Prabhala R.H., Neri P., Bae J.E., et al. Dysfunctional T regulatory cells in multiple myeloma. Blood 107 (2006) 301-304